Pricing Log in Create free account
Friday 6 November 2026 Export MDXHF’s income statement to Excel — free account

MedX Health Corp.

MDXHF Healthcare Diagnostics & Research

MedX Health Corp.’s revenue for fiscal 2025 (year ended December 2025) was $338,700.00, down 5.23% from fiscal 2024.

Revenue
+33.6%
EPS
−6.06%
Free cash flow
+41.6%
Total debt
−8.75%

Quarter to June 2026, against a year earlier

0.03 0.00 0.00%
Market cap
$103.2M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
2/9
Altman Z
−157.11
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 95.47%

Capital & Financial Ratios $m

Size
Market Cap 103.16
Revenue ttm 0.41
Net income ttm (4.43)
Free cash flow ttm (2.71)
Net debt Q 2.29
Valuation
P/E 0.00
Forward P/E (0.32) (negative: loss-making)
Price / sales 23.85 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.02 (below 1: weak)
Debt / equity Q (0.30) (negative: negative equity)
Interest coverage Q (3.16)
Growth
Revenue growth Q +33.59% (above 0%: growing)
Operating income growth Q −30.46% (below 0%: shrinking)
EPS, this year +54.50% (at or above 15%: strong)
EPS, next year A +38.61% (at or above 15%: strong)
Revenue, next year A +31,947.37% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 29.4×, against a ten-year median of 0.4×; over the ten years it ranged from −1.1× in 2022 to 48.0× in 2025.

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 22 0 0 0
Receivables 11 0 0 0
Inventory 3 0 0 0
Other 2 — — —
38 1 0 0
2023 2024 2025 Q'26
Payables 9 2 2 2
ST’ Debt 1 1 1 1
Other 9 33 37 —
20 6 7 7

Compound Annual Growth %

10y 5y 3y
Sales — (55.05%) (79.09%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Dec 2023 Estimate −0.28 Actual −0.39

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Dec 2023 −0.28 −0.39 Miss by 0.11

EPS $

Mar Jun Sep Dec Year
’26 0.00 0.00 — — —
’25 0.00 0.00 0.00 0.00 (0.02)
’24 0.00 0.00 0.00 0.00 (0.01)
’23 (0.05) (0.30) (0.40) (0.39) (1.66)
’22 (0.05) (0.70) (0.05) (1.10) (2.80)
’21 — (0.11) — (0.10) (0.24)
’20 — (0.16) — (0.17) (3.44)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 0
’24 0 0 0 0 0
’23 15 17 19 19 70
’22 6 7 11 13 37
’21 — 11 5 11 22
’20 — 10 — 9 18
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 0 (1) (1) (1) (3)
’24 0 (1) (1) 0 (2)
’23 (4) (6) (4) (7) (21)
’22 (9) (6) (9) (10) (34)
’21 — (12) (17) (6) (23)
’20 — (12) — (20) (20)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (1) (1) (1) (1) (3)
’24 (1) (1) (1) (1) (3)
’23 (5) (7) (5) (8) (24)
’22 (9) (7) (10) (11) (37)
’21 — (12) (18) (6) (23)
’20 — (12) — (21) (21)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 29 43 33 13 18 22 37 70 0 0 0 (38.9%) 109 123 136 +637.3%
Gross margin, % 60.76 69.40 48.62 (28.77) 43.58 47.50 51.87 62.58 39.65 (11.51) (1.89) (72.3) pt
EBT (13) (13) (37) (49) (29) (29) (44) (43) (3) (5) (4) (10.8%)
EBT margin, % (44.33) (30.61) (114.42) (370.60) (155.27) (130.41) (118.86) (61.40) (745.91) (1,329.23) (1,087.83) (1,284.9) pt
Net income (13) 0 (37) (48) (27) (27) (38) (27) (3) (5) (4) (10.8%)
Per share, $
Per share, $ Revenue 0.62 0.87 5.67 2.12 2.22 0.18 2.36 2.70 0.00 0.00 0.00 (50.5%)
Earnings (0.27) (0.27) (6.47) (7.74) (3.44) (0.24) (2.80) (1.66) (0.01) (0.02) (0.01) (27.5%)
Cash flow (0.34) (0.22) (5.77) (4.06) (2.43) (0.19) (2.17) (0.83) (0.01) (0.01) (0.01) (33.3%)
Capex 0.00 0.00 0.00 0.00 (0.06) (0.01) (0.18) (0.11) 0.00 0.00 0.00 n/m
Free cash flow (0.34) (0.22) (5.77) (4.06) (2.50) (0.19) (2.35) (0.93) (0.01) (0.01) (0.01) (33.3%)
Book value 1.14 0.88 10.40 3.54 0.70 0.39 0.59 0.28 (0.02) (0.02) (0.02) n/m
Shares, m 46 50 6 6 8 121 16 26 267 296 314 +23.0%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 0.00 0.00 0.00 0.26 0.26 0.01 0.02 0.00 8.75 23.85 0.9
P/B 0.17 0.17 0.17 0.23 1.40 0.20 0.03 0.15 0.00 0.00 0.00 0.3
EV/Sales 0.00 0.00 0.00 0.00 0.24 (0.95) 0.63 0.26 5.93 12.29 29.40 1.8
EV/FCF 0.00 0.00 0.00 0.00 (0.13) 0.63 (0.60) (0.62) (0.47) (0.79) (2.33) (0.2)
Cash, $m
Cash, $m Operating cash flow (16) (11) (33) (25) (20) (23) (34) (21) (2) (3) (3) (17.9%)
Capex (5) (5) (2) 0 (1) (1) (3) (3) (1) 0 (1) (59.1%)
Free cash flow (16) (11) (33) (25) (21) (23) (37) (24) (3) (3) (3) (17.9%)
Balance, $m
Balance, $m Working capital 39 26 42 23 10 50 11 19 (5) (7) (7) n/m
Net debt (30) (16) (30) (12) (1) (44) 23 17 2 1 2 n/m
Shareholders’ equity 53 44 60 22 6 47 9 7 (6) (7) (8) n/m
Returns, %
Returns, % ROA (19.85) (38.84) (52.22) (80.10) (73.96) (54.25) (45.36) (34.72) (4.11) (784.34) (840.71) (764.5) pt
ROIC 0.00 0.00 0.00 0.00 (338.36) (538.20) (77.00) (69.39) 0.00 0.00 0.00 0.0 pt
ROE (26.03) (27.25) (72.01) (118.02) (204.65) (109.96) (156.70) (521.70) (540.15) 68.26 63.71 +94.3 pt
People
People Employees — — — — — — — — — — — —
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

MedX Health Corp. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MYGN Myriad Genetics, Inc. $601.6M — (loss-making) — (loss-making) −10.51% (below 0%: shrinking) n/m +43.90% (above 0%: growing) 66.60% (20.40%) Compare
FLGT Fulgent Genetics, Inc. $513.4M — (loss-making) — (loss-making) +7.54% (above 0%: growing) n/m +2,058.74% (above 0%: growing) 35.33% (24.94%) Compare
BDSX Biodesix, Inc. $209.3M — (loss-making) — (loss-making) +10.44% (above 0%: growing) n/m +12.78% (above 0%: growing) 0.00% (25.42%) Compare
XGN Exagen Inc. $184.1M — (loss-making) — (loss-making) +15.92% (above 0%: growing) n/m +211.34% (above 0%: growing) 61.27% (8.64%) Compare
BNR Burning Rock Biotech Limited Sponsored ADR $116.5M — (loss-making) 11.1× −4.22% (below 0%: shrinking) n/m +46.01% (above 0%: growing) 72.58% (13.36%) Compare
MDXHF MedX Health Corp. $103.2M — (loss-making) — (loss-making) +33.59% (above 0%: growing) n/m +41.60% (above 0%: growing) 37.19% (1,027.95%)
IMDX Insight Molecular Diagnostics Inc. $80.5M — (loss-making) — (loss-making) −53.86% (below 0%: shrinking) n/m −54.02% (below 0%: shrinking) 65.69% (4,770.71%) Compare
QUCY Quantum Cyber N.V $60.8M — (loss-making) — (loss-making) +11.12% (above 0%: growing) n/m +26.73% (above 0%: growing) 62.71% 0.00% Compare
PRPO Precipio, Inc. $33.3M — (loss-making) 15.4× +24.18% (above 0%: growing) n/m +79.59% (above 0%: growing) 44.67% (8.53%) Compare
Median of peers $150.3M — — +8.99% — +44.96% 61.99% (16.88%)

All 49 Diagnostics & Research stocks →

MedX Health Corp. (MDXHF) Latest News

5 Oct

Impact 4 · · Business Wire

25 Jun

Impact 4 · · Business Wire

27 Feb

Impact 4 · · Business Wire

2 Feb

Impact 3 · · Business Wire

15 Dec

Impact 4 · · Business Wire

6 Nov

Impact 3 · · Business WireMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT Newswires

6 Oct

Impact 3 · · MT Newswires

3 Oct

Impact 3 · · Business Wire

25 Sep

Impact 4 · · Business Wire

9 Sep

Impact 3 ·

8 Sep

Impact 4 · · Business Wire
Impact 3 · · Business WireACCESS NewswireNewsfileBusiness Wire

20 Aug

Impact 3 ·

25 Jul

Impact 3 ·

22 Jul

Impact 4 · · Business Wire

12 Jun

Impact 3 ·

9 Jun

Impact 3 · · Business Wire

22 May

Impact 3 · · Business Wire

21 May

Impact 4 · · Business Wire

15 May

Impact 4 ·

6 May

Impact 3 · · Business Wire

7 Apr

Impact 3 · · Business Wire

25 Feb

Impact 3 ·

6 Aug

Impact 3 · · Business Wire

26 Jun

Impact 3 · · Business Wire

5 Jun

Impact 3 · · Simply Wall St.

31 May

Impact 3 · · Business Wire

1 May

Impact 3 · · Business Wire

28 Feb

Impact 4 · · Business Wire

25 Jan

Impact 4 · · Business Wire
stockrow.com/MDXHF · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com